Pfizer/$PFE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Ticker
$PFE
Sector
Primary listing
NYSE
Employees
81,000
Headquarters
Website
Pfizer Metrics
BasicAdvanced
$139B
14.15
$1.73
0.42
$1.71
7.04%
Price and volume
Market cap
$139B
Beta
0.42
52-week high
$27.69
52-week low
$20.92
Average daily volume
76M
Dividend rate
$1.71
Financial strength
Current ratio
1.282
Quick ratio
0.904
Long term debt to equity
61.898
Total debt to equity
66.531
Dividend payout ratio (TTM)
98.75%
Interest coverage (TTM)
6.59%
Profitability
EBITDA (TTM)
24,530
Gross margin (TTM)
74.81%
Net profit margin (TTM)
15.66%
Operating margin (TTM)
28.43%
Effective tax rate (TTM)
-7.48%
Revenue per employee (TTM)
$780,000
Management effectiveness
Return on assets (TTM)
5.19%
Return on equity (TTM)
10.60%
Valuation
Price to earnings (TTM)
14.152
Price to revenue (TTM)
2.209
Price to book
1.5
Price to tangible book (TTM)
-5.03
Price to free cash flow (TTM)
13.369
Free cash flow yield (TTM)
7.48%
Free cash flow per share (TTM)
1.827
Dividend yield (TTM)
7.00%
Forward dividend yield
7.04%
Growth
Revenue change (TTM)
3.89%
Earnings per share change (TTM)
131.89%
3-year revenue growth (CAGR)
-14.34%
10-year revenue growth (CAGR)
2.74%
3-year earnings per share growth (CAGR)
-30.71%
10-year earnings per share growth (CAGR)
2.63%
3-year dividend per share growth (CAGR)
-6.97%
10-year dividend per share growth (CAGR)
4.45%
What the Analysts think about Pfizer
Analyst ratings (Buy, Hold, Sell) for Pfizer stock.
Bulls say / Bears say
Pfizer’s $6 billion licensing deal with China’s 3SBio Inc grants global (ex-China) rights to the cancer candidate SSGJ-707 and includes a $100 million equity stake, significantly bolstering its oncology pipeline and international collaboration footprint. (Reuters)
The U.S. FTC granted early antitrust clearance for Pfizer’s proposed $7.3 billion acquisition of Metsera, de-risking its entry into the high-growth obesity market with potential blockbuster GLP-1 therapies. (Reuters)
The FDA’s full approval of Pfizer-BioNTech’s Comirnaty vaccine for adults 65 and older and at-risk individuals aged 5–64 extends its COVID-19 franchise and broadens the addressable immunization population. (Reuters)
Pfizer missed first-quarter 2025 revenue estimates as Paxlovid sales plunged to $491 million versus $794 million expected, underscoring volatility in its COVID-19 treatment revenues. (Reuters)
The Eliquis 360 Support program will offer the drug at more than a 40% discount to cash-paying patients, potentially compressing margins on one of Pfizer’s top-selling products. (Reuters)
A U.S. House Judiciary Committee subpoena of former Pfizer executive Philip Dormitzer over alleged election-timed delays in COVID-19 vaccine trial results injects regulatory and reputational risk into the company’s vaccine narrative. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
Pfizer Financial Performance
Revenues and expenses
Pfizer Earnings Performance
Company profitability
Pfizer News
AllArticlesVideos
Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war
WSJ12 hours ago
Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports
Reuters14 hours ago
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Reuters2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Pfizer stock?
Pfizer (PFE) has a market cap of $139B as of November 08, 2025.
What is the P/E ratio for Pfizer stock?
The price to earnings (P/E) ratio for Pfizer (PFE) stock is 14.15 as of November 08, 2025.
Does Pfizer stock pay dividends?
Yes, the Pfizer (PFE) stock pays dividends to shareholders. As of November 08, 2025, the dividend rate is $1.71 and the yield is 7.04%. Pfizer has a payout ratio of 98.75% on a trailing twelve-month basis.
When is the next Pfizer dividend payment date?
The next Pfizer (PFE) dividend payment is scheduled for December 01, 2025.
What is the beta indicator for Pfizer?
Pfizer (PFE) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.